Brokerages Set Oncternal Therapeutics, Inc. (NASDAQ:ONCT) PT at $15.20

Shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) have earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $15.20.

A number of equities research analysts have issued reports on the stock. Oppenheimer began coverage on shares of Oncternal Therapeutics in a research note on Tuesday, April 6th. They set an “outperform” rating and a $14.00 target price for the company. Brookline Capital Management restated a “buy” rating and set a $16.00 price target on shares of Oncternal Therapeutics in a report on Tuesday, March 30th. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Oncternal Therapeutics in a report on Friday, April 16th. Zacks Investment Research upgraded shares of Oncternal Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Brookline Capital Acquisition began coverage on shares of Oncternal Therapeutics in a report on Tuesday, March 30th. They set a “buy” rating and a $16.00 price target on the stock.

Oncternal Therapeutics stock traded down $0.19 during midday trading on Thursday, reaching $4.31. The stock had a trading volume of 14,522 shares, compared to its average volume of 1,036,904. The firm has a fifty day moving average of $5.05. Oncternal Therapeutics has a twelve month low of $1.49 and a twelve month high of $10.56. The firm has a market cap of $212.78 million, a price-to-earnings ratio of -5.45 and a beta of 1.74.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings data on Thursday, May 6th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The firm had revenue of $0.75 million during the quarter, compared to analyst estimates of $1.11 million. Oncternal Therapeutics had a negative return on equity of 29.91% and a negative net margin of 520.20%. As a group, equities analysts expect that Oncternal Therapeutics will post -0.59 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of ONCT. BlackRock Inc. boosted its position in shares of Oncternal Therapeutics by 213.6% during the 1st quarter. BlackRock Inc. now owns 1,075,652 shares of the company’s stock valued at $8,949,000 after acquiring an additional 732,630 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Oncternal Therapeutics during the 1st quarter valued at about $3,621,000. Parkman Healthcare Partners LLC boosted its position in shares of Oncternal Therapeutics by 106.7% during the 1st quarter. Parkman Healthcare Partners LLC now owns 778,785 shares of the company’s stock valued at $6,479,000 after acquiring an additional 402,006 shares in the last quarter. Brighton Jones LLC acquired a new stake in shares of Oncternal Therapeutics during the 1st quarter valued at about $2,770,000. Finally, Tri Locum Partners LP acquired a new position in Oncternal Therapeutics in the fourth quarter valued at about $1,400,000. Institutional investors and hedge funds own 20.03% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia.

See Also: Strangles

Analyst Recommendations for Oncternal Therapeutics (NASDAQ:ONCT)

Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.